Last reviewed · How we verify
Fruquintinib in Combination with Sintilimab — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Fruquintinib in Combination with Sintilimab (Fruquintinib in Combination with Sintilimab) — Hutchmed.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Fruquintinib in Combination with Sintilimab TARGET | Fruquintinib in Combination with Sintilimab | Hutchmed | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Fruquintinib in Combination with Sintilimab CI watch — RSS
- Fruquintinib in Combination with Sintilimab CI watch — Atom
- Fruquintinib in Combination with Sintilimab CI watch — JSON
- Fruquintinib in Combination with Sintilimab alone — RSS
Cite this brief
Drug Landscape (2026). Fruquintinib in Combination with Sintilimab — Competitive Intelligence Brief. https://druglandscape.com/ci/fruquintinib-in-combination-with-sintilimab. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab